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Objective:  Elevated  mean  platelet  volume  (MPV)  has  been  proposed  as  a risk  factor  for  coronary  artery
disease  (CAD)  and  is  associated  with  poor  clinical  outcome  in acute  coronary  syndrome  (ACS).  We  aimed
to evaluate  the  association  of MPV  with  presence  of  coronary  collateral  vessel  (CCV)  in  patients  with  ACS.
Methods:  A total  of  417  patients  with  ACS  were  included  in  the  study.  All  patients  underwent  coronary
angiography  on  the  ﬁrst day  after admission  and  patients  with  a greater  than  or equal  to  80%  obstruction
in  at  least  one  epicardial  coronary  artery  were  included  in  the  study.  The  CCVs are  graded  according  to  the
Rentrop  scoring  system  and  a Rentrop  grade  0 was  accepted  as  no CCV  development  (Group  1),  Rentropean platelet volume
oronary collateral vessel
cute coronary syndrome
Grade  1–2–3  were  accepted  as  presence  of CCV  development  (Group  2).
Results:  The  median  of  MPV  was  9.1  ± 1.4  ﬂ.  Mean  age  was 60 ± 12 year.  Group  1  consisted  of  233 (55.9%)
patients  and  Group  2 consisted  of 184  (44.1%)  patients.  Presence  of CCV  was  signiﬁcantly  associated  with
high  levels  of  MPV  (p  =  0.005).  Presence  of  CCV  was  also  associated  with  presence  of diabetes  and  systolic
blood  pressure.
Conclusion:  High  MPV  on  admission  was  associated  with  presence  of  CCV  in  patients  with ACS.
3  Jap©  201
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Platelets play an important role in the pathophysiology of
therosclerosis and prothrombotic events leading to ACS [1].  Mean
latelet volume (MPV) is a useful biomarker of platelet activ-
ty [1,2]. Platelets are heterogeneous with respect to their size
nd reactivity. Large platelets are metabolically and enzymatically
ore active than small ones and have higher thrombotic poten-
ial [3].  Increase in MPV  is associated with poor clinical outcome
nd impaired angiographic reperfusion in patients with myocardial
nfarction (MI) [4].
Coronary collateral vessels (CCVs) can provide a perfusion
eserve in case of increased myocardial oxygen demand. Coronary
ollaterals can limit the myocardial ischemia and can protect the
iable myocardium in patients with ACS [5–7]. Proliferation of CCV
ccurs in response to myocardial ischemia. The presence of CCV
s correlated with well clinical outcomes in patients with ACS [8].
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The complex mechanisms mediating the development of CCV in the
heart are not well-understood. Some mediators (such as C-reactive
protein, uric acid, circulating endothelial progenitor cells) were
investigated to explain this relationship, but there is no conclusive
evidence to explain this relationship [9,10].  Moreover, as increased
MPV  predicted the risk of coronary artery disease (CAD) and cardiac
mortality, it may  also be interesting to examine whether levels of
MPV  predict the presence of CCVs, one of the major predictors of
mortality in patients with ACS. In the present study, we hypothe-
sized that levels of serum MPV  could be independently associated
with the development of CCV after adjustment for traditional car-
diovascular risk factors.
Methods
Patients
A total of 670 consecutive and unselected patients who  were
admitted to hospital with ACS were prospectively included in
the study. Patients with a history of renal disease, a history of
past coronary intervention or coronary artery bypass grafting, a
history of inﬂammatory rheumatic disease, a history of chronic
vier Ltd. All rights reserved.
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Table 1
Baseline clinical characteristics of patients.
Age (years) 60 ± 12
Female (n, %) 98 (23.5%)
Male (n, %) 319 (76.5%)
Smoking (n, %) 212 (50.8%)
Platelet count (×103/l) 229 ± 64
MPV  (ﬂ) 9.1 ± 1.4
Rentrop 0 (n, %) 233 (55.9%)
Rentrop 1 (n, %) 84 (20.1%)
Rentrop 2 (n, %) 45 (10.8%)
Rentrop 3 (n, %) 55 (13.2%)
systolic blood pressure (r = −0.178, p = 0.017), and serum creatinine
(r = −0.126, p = 0.010).
Table 2
Relation between presence of coronary collaterals and baseline characteristic of
patients.
Rentrop 0 Rentrop 1–2–3 p
Age (years) 59 ± 12 60 ± 12 0.171
Gender (male, %) 179 (76.8%) 140 (76.0%) 0.860
Smoking (n, %) 116 (49.7%) 96 (52.1%) 0.628
Hypertension (n, %) 40 (17.2%) 42 (22.8%) 0.149
Diabetes (n, %) 27 (11.6%) 37 (20.1%) 0.017
USAP (n, %) 73 (31.3%) 56 (30.5%) 0.844
NSTEMI (n, %) 81 (34.8%) 77 (41.8%) 0.139
STEMI (n, %) 79 (33.9%) 51 (27.7%) 0.140
Systolic BP (mmHg) 120 (90–190) 110 (80–210) 0.041
Diastolic BP (mmHg) 70 (50–110) 70 (50–130) 0.130
USAP, unstable angina pectoris; NSTEMI, non-ST elevation myocardial infarction;
STEMI, ST elevation myocardial infarction; BP, blood pressure.
Table 3
Relation between presence of coronary collaterals and baseline laboratory ﬁndings
of patients.
Rentrop 0 Rentrop 1–2–3 p
MPV  (ﬂ) 8.9 ± 1.4 9.3 ± 1.4 0.005
Glucose (mg/dl) 106 (57–461) 108 (60–463) 0.392
WBC  (×109/l) 10.1 ± 3.5 10.1 ± 3.2 0.926
BUN (mg/dl) 23 (5–47) 21 (9–46) 0.165
Creatinine (mg/dl) 0.9 (0.2–1.4) 0.9 (0.6–1.4) 0.169
Troponin (ng/ml) 0.4 (0–79) 0.7 (0–100) 0.299
CK-MB (IU/l) 25 (1–693) 33 (3–426) 0.306
Total cholesterol (mg/dl) 181.9 ± 40.7 185.1 ± 45.6 0.376
LDL  cholesterol (mg/dl) 113.9 ± 35.7 119.7 ± 39.5 0.181
HDL cholesterol (mg/dl) 35 (16–89) 34 (20–124) 0.674
Triglyceride (mg/dl) 121 (39–675) 123 (22–849) 0.786
Hemoglobin (mg/dl) 14.4 (8.2–19.0) 14.6 (8.1–58.0) 0.366
Platelets (×103/l) 231.1 ± 61.2 226.7 ± 67.7 0.685
Total protein (g/dl) 6.6 ± 0.6 6.6 ± 0.6 0.35396 M. Duran et al. / Journal o
bstructive pulmonary disease, and taking aspirin/clopidogrel/
arfarin/unfractionated heparin and low molecular weight hep-
rin were excluded. The patients with less than 80% stenosis in
he coronary angiography were also excluded from the study [11].
inally, 417 patients were included in the study. According to coro-
ary angiography results, patients were divided into two  groups as
roup 1 (no CCV) and Group 2 (presence of CCV). Informed consent
as obtained from all patients. The study was approved by our local
thics committee. All demographic and clinical data were collected
rospectively.
aboratory analysis
In all cases, blood samples were drawn at admission before start-
ng any medication (Thermo Clinical Lab system with Konelab 60
 kids, Helsinki, Finland). For assessment of MPV, blood samples
ere taken and put into tubes containing tripotassium ethylene-
iaminetetraacetic acid before clopidogrel, heparin, or tiroﬁban
dministration and studied within 20 min  with an automated
ow counter (Sysmex SE 9500, Roche, Mannheim, Germany). The
xpected values for MPV  in our laboratory ranged from 7.0 to 10.5 ﬂ.
oronary angiography
Quantitative coronary angiography was performed by two expe-
ienced interventional cardiologists who had no knowledge of the
atients’ clinical information by the Judkins or Sones technique.
oronary vessel disease was described as 80% or greater degree
f diameter stenosis in at least one coronary artery. Collateral cir-
ulation was graded according to the Rentrop classiﬁcation. The
ollateral circulation was based on the injection that best opaciﬁed
he occluded vessel: 0 = no visible ﬁlling of any collateral vessels;
 = ﬁlling of side branches of the artery to be perfused by col-
ateral vessels without visualization of the epicardial segment;
 = partial ﬁlling of the epicardial segment by collateral vessels; and
 = complete ﬁlling of the epicardial segment by collateral vessels
12]. Rentrop grade 0 accepted as no development of CCV and Ren-
rop grade ≥1 was accepted as presence of CCV (Group 2). Also,
entrop grades 0–1 were accepted as bad CCV development, Ren-
rop grades 2–3 were accepted as well CCV development.
tatistical analysis
All analyses were performed using SPSS V 16.0 for windows
version 16.0, SPSS, Chicago, IL, USA). Quantitative variables were
xpressed as mean value ± SD for parametric variables and median
nd minimum–maximum levels for non-parametric variables.
omparison of parametric values between two groups was  per-
ormed by means of independent-samples t test. Comparison of
on-parametric values between two groups was performed by
ann–Whitney U-test. Categorical variables were compared by the
hi-squared test. Pearson test used for correlation parametric vari-
bles and Spearman test was used for non-parametric variables.
wo-tailed p-value < 0.05 was considered statistically signiﬁcant.
ultivariate logistic regression analysis was performed to evalu-
te the effects of gender, diabetes, systolic blood pressure, blood
rea nitrogen (BUN), creatinine, hemoglobin, total protein, albu-
in, and MPV  on development of good CCV. Receiver operating
haracteristics (ROC) analysis was performed. The best cutoff value
as determined and the sensitivity and speciﬁcity at that point
ere determined.esults
Table 1 shows baseline clinical characteristics of the patients.
he mean platelet count was 229 ± 64 (×103) and the mean MPVMPV, mean platelet volume.
was 9.1 ± 1.4 ﬂ. Mean age was 60 ± 12 years. Rentrop 0, 1, 2, and
3 were determined in, respectively, 233 (55.9%), 84 (20.1%), 45
(10.8%), and 55 (13.2%) patients. Rentrop 1–2–3 (presence of CCV)
were determined in 184 (44.1%) patients. Tables 2 and 3 show the
relation between the presence of CCV and baseline clinical and
laboratory characteristics of the patients. Presence of CCV was  sig-
niﬁcantly associated with high levels of MPV  (p = 0.005) (Table 3
and Fig. 1). Presence of CCV was  also associated with presence of
diabetes and low systolic blood pressure. Also the development of
good CCV (Rentrop 2–3) was  associated with high levels of MPV
(p = 0.016) (Fig. 1).
Rentrop score was  associated with MPV  (r = 0.181 p < 0.0001),Albumin (g/dl) 3.9 ± 0.4 3.8 ± 0.5 0.163
MPV, mean platelet volume; WBC, white blood cell; BUN, blood urea nitrogen; CK-
MB,  creatinine kinase MB  fraction; LDL, low-density lipoprotein; HDL, high-density
lipoprotein.
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fig. 1. Relation between presence of good coronary collaterals and mean platelet
olume.
At multivariate analysis, elevated MPV  levels were independent
redictors for the presence of CCV (OR: 1.260, conﬁdence interval
.017–1.560, p = 0.034).
The predictive value of serum MPV  level for presence of collat-
rals, (sensitivity of 61% and speciﬁcity of 50%, area under the ROC
urve = 0.543) was 8.85 ﬂ (Fig. 2).
iscussion
Although the exact mechanism has not been fully elucidated,
everal factors were deﬁned as contributors to development of CCV.
ffect of platelet volume on coronary adverse outcomes is well
nown in the literature [1–4]. However, there are insufﬁcient data
egarding the relation between MPV  and CCV.
Well developed CCVs can limit myocardial ischemia, may  min-
mize the infarct size, and can protect the viable myocardium in
atients with ACS [5–8]. The absence of CCV is correlated with
ad clinical outcomes in patients with ACS [11]. Resting distal
oronary pressure consistently falls as stenosis severity exceeds
0% [11]. Although the underlying mechanism remains unchar-
cterized, myocardial ischemia, growth factors [such as ﬁbroblast
rowth factor (FGF) and vascular endothelial growth factor], vari-
us cells such as endothelial, monocytes, smooth muscle, cytokines,
nd shear stress are likely factors that contribute to initiating
nd remodeling for collateral development during tissue hypoxia
13–16]. Endothelial dysfunction is associated with poorer collat-
ral growth [17]. Also duration of angina pectoris and the extent of
AD are well-established determinants of CCVs [18].
Platelets play a key role in the pathogenesis, morbidity, and mor-
ality of ACS [19]. Increase in platelet activation is associated with
ig. 2. The receiver operating characteristic (ROC) curve for mean platelet volume
or  predicting presence of coronary collateral vessels.ology 61 (2013) 295–298 297
CAD, carotid artery disease, and transplant vasculopathy [20–23].
Elevated MPV  has been recognized as an independent risk factor
for MI  [24]. Large platelets are metabolically and enzymatically
more active than smaller ones and secrete and express more medi-
ators such as adhesive proteins (ﬁbrinogen, thrombospondin, and
ﬁbronectin), growth factors [platelet-derived growth factor (PDGF),
transforming growth factor-,  basic FGF], chemotactic and mito-
genic factors [platelet factor 4 (PF4), coagulation factors (factor V,
factor XI), and cytokine-like factors (interleukin-1, CD40 ligand)]
[25–27]. Chemokines that are secreted from active platelets also
stimulate smooth muscle cells and contribute to inﬂammation and
atherogenesis [26,28]. Inﬂammatory markers also contribute to
absence of CCV via endothelial dysfunction [29].
Therefore in this study, we suggest the hypothesis that
platelet size may  play a role in the presence and development
of CCVs and high levels of MPV  were signiﬁcantly associated
with the presence of CCV in patients with ACS. The associ-
ation between elevated MPV  and development of good CCVs
could be explained by chemotactic and mitogenic factors which
are expressed by activated platelets (such as PDGF and PF4).
Platelets with high levels of MPV  secrete and express more sub-
stances including PDGF, serotonin, PF4, chemotactic and mitogenic
factors contributing to vascular arteriogenesis and angiogenesis
which are the ﬁrst steps for developing CCV. Endothelial dys-
function and large/active platelets in CAD may  contribute to
the severity of CAD with silent or obvious ischemic attacks and
indirectly development of collateral formation by stress-induced
ischemia.
Recently, Ege et al. reported that MPV  levels were signiﬁcantly
higher and Gensini score was signiﬁcantly lower in the patients
who had inadequate CCV in patients with CAD [30]. They studied
210 patients who  had coronary stenosis ≥50% in at least one coro-
nary artery. In this study, patients in Rentrop grades 0, 1, and 2 were
classiﬁed as group 1 CCV inadequate and patients in Rentrop grade 3
were classiﬁed as group 2 (CCV adequate). As we mentioned above,
development of CCV is triggered by the gradient between arter-
ies due to at least >70% coronary stenosis and Ege et al. evaluated
patients with ≥50% in at least one coronary artery.
Previous reports showed that there is a close relationship
between MPV  and other prognostic factors, such as smoking, dia-
betes, obesity, hypertension, and hypercholesterolemia [31–34].
But our study showed no clear association between MPV  and
known ischemic heart disease risk factors. We did not ﬁnd any
association between development of CCV and age, hypertension,
smoking, or gender. In our study, the presence of CCVs in dia-
betic patients was better than in non-diabetics, in contrast to other
reports [17]. But there were not a sufﬁcient number of diabetic
patients to assess the impact of diabetes on the presence of collat-
erals. Thus, we  think that it is not possible to determine the effects
of diabetes on the presence of collaterals according to the results
of this study.
Although the mechanism is still unclear, the increased
megakaryocyte ploidy is positively and number of megakary-
ocytes is negatively correlated with platelet volume [4]. We did
not observe any association between elevated MPV and the total
platelet count.
Our study group includes only patients with ACS. We  know that
collaterals take time to develop but some studies showed early
angiographic evidence of collateral circulation in patients with
acute MI  [35] and non-ST elevation MI  [36]. Patients with ACS and
a well-developed collateral circulation may  have proﬁted from a
gradually developing stenosis via slow growth of mural thrombi.Finally, different methods can be used to analyze platelet acti-
vation [37]. All tests have some limitations. However, MPV  provide
an important, simple, effortless, and cost-effective marker which
can be useful for evaluation of platelet activation.
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In conclusion, MPV  on admission was associated with develop-
ent of CCV positively in patients with ACS. Mean platelet volume
s a simple and cost-effective marker that can be used to analyze
latelet activation and their relation with coronary collaterals.
tudy limitations
Firstly, there are no data about physical activity of the patients,
hich encourages the development of CCVs. Secondly, angiogra-
hic techniques do not demonstrate vessels of which the luminal
iameter is 100 mm or less. Thirdly, the study population did not
ontain patients with CAD but not ACS. Fourthly, although there
s a deﬁnite ceiling to predict CCVs by MPV  as shown in Fig. 2, we
id not use this level of MPV  for dividing patients into two  groups
ecause of its low speciﬁcity and sensitivity.
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